首页> 外文期刊>International Journal of Basic & Clinical Pharmacology >Teratogenicity study in rats of commonly used calcium channel blockers
【24h】

Teratogenicity study in rats of commonly used calcium channel blockers

机译:常用钙通道阻滞剂对大鼠的致畸作用研究

获取原文
获取外文期刊封面目录资料

摘要

Background: Calcium channel blockers (CCBs) are popular medicines used to treat hypertension, tachyarrhythmias or angina during pregnancy. Lack of adequate safety data has however created an uncertainty in the use of CCBs in pregnancy. Nifedipine has been reportedly associated with a variety of embryotoxic and fetotoxic effects in animals. Therefore, this study was undertaken to establish whether or not the commonly used CCBs (nifedipine and amlodipine) would produce teratogenic effects in rats. Methods: Twenty pregnant rats were randomly assigned to each of the treatment and control groups. Nifedipine and amlodipine were used in three dose levels of 5, 10, 20 mg/kg and 0.5, 1, 2 mg/kg body weight respectively to test its teratogenic effects. The maximum dose of the test drugs used in our study was ten times the maximum recommended human dose. The drugs were administered to the pregnant rats using nasogastric tubes from day 6 through day 15 of pregnancy. The number of live births, stillbirths, litter sizes, crown-rump lengths, birth weights and gross abnormalities of the pups delivered were observed and recorded. Skeletal changes and soft tissue changes were also observed in the pups delivered to treated pregnant rats. Results: It was found that nifedipine and amlodipine did not produce any teratogenic effects in rats at doses 2.5 to 10 times the recommended human dose. None of the pups showed any gross morphological, skeletal or visceral defects. Conclusions: Nifedipine and amlodipine appear to be safe during pregnancy in therapeutic doses.
机译:背景:钙通道阻滞剂(CCBs)是用于治疗妊娠期高血压,快速性心律失常或心绞痛的流行药物。然而,缺乏足够的安全性数据导致在怀孕期间使用CCB的不确定性。据报道,硝苯地平对动物具有多种胚胎毒性和胎儿毒性作用。因此,本研究旨在确定常用的CCB(硝苯地平和氨氯地平)是否会在大鼠中产生致畸作用。方法:将20只妊娠大鼠随机分为治疗组和对照组。硝苯地平和氨氯地平分别以5、10、20 mg / kg体重和0.5、1、2 mg / kg体重的三种剂量水平使用,以测试其致畸作用。在我们的研究中使用的测试药物的最大剂量是推荐的最大人类剂量的十倍。从怀孕的第6天到第15天,使用鼻胃管向怀孕的大鼠给药。观察并记录活产婴儿的数量,死产,产仔数,冠臀长,出生体重和出生的幼仔的严重异常。在交付给治疗的怀孕大鼠的幼崽中也观察到骨骼变化和软组织变化。结果:发现硝苯地平和氨氯地平在人类推荐剂量的2.5至10倍剂量下不会对大鼠产生任何致畸作用。幼犬均未显示任何明显的形态,骨骼或内脏缺陷。结论:硝苯地平和氨氯地平在治疗期间似乎是安全的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号